Clinical trial
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With…
NCT00413829 · Insel Gruppe AG, University Hospital Bern, Other · Completed
Key facts
| NCT number | NCT00413829 |
|---|---|
| Title | Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB) |
| Official title | Open-label, Phase II Study Assessing Immediate Effects of Lucentis®(Ranibizumab) Administered in Conjunction With Photodynamic Therapy With Visudyne® in Patients With Choroidal Neovascularization Secondary to AMD |
| Lead sponsor | Insel Gruppe AG, University Hospital Bern, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Age Related Macular Degeneration |
| Intervention type | Drug |
| Interventions | Intravitreal ranibizumab with photodynamic therapy |
| Enrollment | 20 |
| Start date | Oct 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | Dec 20, 2006 |
| Last update posted | Jan 14, 2010 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: